Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.
about
Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsA pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesTreatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.'Old' antibiotics for emerging multidrug-resistant bacteriaComparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration.Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsAutophagy regulates colistin-induced apoptosis in PC-12 cells.Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates.Dosing of colistin-back to basic PK/PD.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingIn vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonateApplication of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killInteraction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelEffect of systemic infection induced by Pseudomonas aeruginosa on the brain uptake of colistin in mice.Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsInfluence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative BacilliPopulation pharmacokinetic analysis of colistin in burn patients.Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaPharmacokinetic evaluation of colistin sodium.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.Polymyxins: wisdom does not always come with age.Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Colistin: understanding and applying recent pharmacokinetic advances.Strategies for the safe use of colistin.The safety of polymyxin antibiotics.Polymyxin B versus colistin: an update.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.
P2860
Q28082546-E70319F0-C97E-4700-886A-9FB0AE02D809Q31059319-5C31E4CE-D7AA-4FD7-81C9-0A1B0FD45473Q33662378-9890C7CD-AB8F-42C9-AD44-4B0E09D45AF7Q33882361-4B87D18E-672A-479C-9A7D-F9CE8746D7F1Q34015375-0B13AE4B-AABD-48CC-9E77-A07DE60C17C8Q34060378-38C38905-02EC-4F87-928D-0C41C1A55BEBQ34108660-21E294E3-35F3-4B86-9194-47AAE282AE50Q34274190-EAE1880E-283E-4302-B675-69DB0973A96BQ34297656-0E022CD8-6668-44E9-9C63-A194B8948F0AQ34320945-4048309C-1DDE-495C-A3FB-9FD48F0327F3Q34327857-9040143D-F4A5-4912-9189-92D27308FAC5Q34346283-9A9EEDBF-137D-472C-9079-14A0F9B04BC8Q34565772-4D3F842A-5F4C-4823-A6D7-BBA64EAF07F4Q34597749-C731558C-7259-49C5-AC3E-53323C2CD2A9Q34922728-B0220B21-96E9-4246-9AA4-399886587BFCQ35065863-EC9FCCA7-FF27-44DD-B8C7-4077B775C3EFQ35169023-A58D0EE5-5667-4FE3-AA63-9E684E33D193Q35169065-387DCEC9-337A-4A4D-A846-E11A29E6CB3FQ35242165-DB40420E-17BF-496F-B50A-A162789B9DF7Q35541277-1B929807-A43F-4D9B-83D3-28A8855CF5A2Q35941284-5F411F6D-7A91-4916-94B9-E19ECF12CB47Q36171581-DF6BC126-510E-41AE-BD88-E2ABC8E6C947Q36171772-9B2505F4-6F5F-4F62-AA55-549BDA670329Q36222127-D2289428-8D09-458C-BA01-C4012D52E206Q36276852-FEE83DC2-18AC-4D1A-ABB0-D741C4241B89Q36276961-87B4A4D0-772C-4EE5-AB78-E653956C24FBQ36335694-239EC2B8-384D-4EA4-8258-BC0ABA407003Q36361921-63810DD2-80FE-4525-8244-AAC7A76E0459Q36438905-EAB40401-BF52-464B-9D92-FF9E328A4B4BQ36785854-1093CDB2-70E9-4C31-A267-099472EEE8B0Q36887819-BE1C06B7-9633-4B1D-B7B0-92E09F324625Q37815508-950DBCDA-03A9-4964-A735-7D2F2045CD44Q38040733-67C3025C-BA2B-4701-B84D-DFEE8D641EC5Q38111213-DCAF37BB-C013-4DB9-BD78-29BC7313A6B2Q38186636-755E81AC-70A1-4EE7-B1D3-AEF40C93FD82Q38246001-40834A63-7A49-48B3-91D8-09E4A1D26734Q38548658-DD39CF58-852E-470A-9FBD-7D21931815DDQ38586123-42043554-DEBD-4134-A809-D28C6AB45C98Q38613051-19E8F419-1E06-46F8-8F43-0064FC1379DEQ38664871-16B46C58-F77D-43FC-A668-DD01F61C8E29
P2860
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Elucidation of the pharmacokin ...... igh and lung infection models.
@ast
Elucidation of the pharmacokin ...... igh and lung infection models.
@en
type
label
Elucidation of the pharmacokin ...... igh and lung infection models.
@ast
Elucidation of the pharmacokin ...... igh and lung infection models.
@en
prefLabel
Elucidation of the pharmacokin ...... igh and lung infection models.
@ast
Elucidation of the pharmacokin ...... igh and lung infection models.
@en
P2093
P2860
P356
P1476
Elucidation of the pharmacokin ...... igh and lung infection models.
@en
P2093
Craig R Rayner
John D Turnidge
Kingsley Coulthard
Rajesh V Dudhani
Robert W Milne
Roger L Nation
P2860
P304
P356
10.1128/AAC.01114-09
P407
P577
2009-12-22T00:00:00Z